MIKEL
TAINTA CUEZVA
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (17)
2024
-
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study
Alzheimer's and Dementia
-
Blood-based multivariate methylation risk score for cognitive impairment and dementia
Alzheimer's and Dementia
2023
-
Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
Genome Medicine, Vol. 15, Núm. 1
2022
2021
-
Replication study of plasma proteins relating to Alzheimer's pathology
Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1452-1464
-
Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort
Biomedicines, Vol. 9, Núm. 11
-
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640
2020
-
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology
Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368
-
Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
Translational Psychiatry, Vol. 10, Núm. 1
-
Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort
Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225
2019
-
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938
-
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
Alzheimer's and Dementia, Vol. 15, Núm. 5, pp. 644-654
-
Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid*
Molecular and Cellular Proteomics, Vol. 18, Núm. 3, pp. 546-560
-
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
Alzheimer's and Dementia, Vol. 15, Núm. 11, pp. 1478-1488
-
Inflammatory biomarkers in Alzheimer's disease plasma
Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 776-787
-
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 742-753
-
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 817-827